Blythe Thomson

2.8k total citations · 1 hit paper
39 papers, 1.7k citations indexed

About

Blythe Thomson is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Blythe Thomson has authored 39 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 18 papers in Public Health, Environmental and Occupational Health and 11 papers in Genetics. Recurrent topics in Blythe Thomson's work include Acute Lymphoblastic Leukemia research (17 papers), Acute Myeloid Leukemia Research (16 papers) and Hematopoietic Stem Cell Transplantation (9 papers). Blythe Thomson is often cited by papers focused on Acute Lymphoblastic Leukemia research (17 papers), Acute Myeloid Leukemia Research (16 papers) and Hematopoietic Stem Cell Transplantation (9 papers). Blythe Thomson collaborates with scholars based in United States, Australia and United Kingdom. Blythe Thomson's co-authors include Franklin O. Smith, Peter Ho, Stephen J. Blakemore, Hal E. Broxmeyer, David Emanuel, Zacharie Brahmi, Patricia K. Kotylo, Kent A. Robertson, Darla Gowan and Jean‐Charles Soria and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Blythe Thomson

38 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

2018 451 citations Antoîne Italiano, Jean‐Charles Soria et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Blythe Thomson United States	15	596	538	375	329	292	39	1.7k
Judith Landman‐Parker France	17	510 0.9×	262 0.5×	321 0.9×	434 1.3×	291 1.0×	47	1.5k
Nick Bown United Kingdom	30	1.3k 2.1×	924 1.7×	597 1.6×	663 2.0×	198 0.7×	74	3.1k
G Paolucci Italy	22	350 0.6×	355 0.7×	352 0.9×	267 0.8×	91 0.3×	90	1.3k
André Baruchel France	22	516 0.9×	757 1.4×	650 1.7×	306 0.9×	161 0.6×	45	1.7k
M. Luisa Paccagnella United States	13	409 0.7×	439 0.8×	619 1.7×	857 2.6×	123 0.4×	22	1.7k
D Hammond United States	23	472 0.8×	556 1.0×	687 1.8×	634 1.9×	101 0.3×	48	2.3k
Vita J. Land United States	27	443 0.7×	803 1.5×	1.1k 3.0×	515 1.6×	96 0.3×	61	2.4k
S N Wolff United States	16	423 0.7×	1.1k 2.0×	274 0.7×	863 2.6×	562 1.9×	22	2.1k
Anne Lennard United Kingdom	20	218 0.4×	414 0.8×	154 0.4×	561 1.7×	240 0.8×	51	1.6k
Mario Sessarego Italy	28	425 0.7×	1.8k 3.3×	465 1.2×	387 1.2×	316 1.1×	122	2.3k

Countries citing papers authored by Blythe Thomson

Since Specialization

Citations

This map shows the geographic impact of Blythe Thomson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Blythe Thomson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Blythe Thomson more than expected).

Fields of papers citing papers by Blythe Thomson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Blythe Thomson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Blythe Thomson. The network helps show where Blythe Thomson may publish in the future.

Co-authorship network of co-authors of Blythe Thomson

This figure shows the co-authorship network connecting the top 25 collaborators of Blythe Thomson. A scholar is included among the top collaborators of Blythe Thomson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Blythe Thomson. Blythe Thomson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Italiano, Antoîne, Jean‐Charles Soria, Maud Toulmonde, et al.. (2018). Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. The Lancet Oncology. 19(5). 649–659. 451 indexed citations breakdown →

Shukla, Neerav, Maureen M. O’Brien, Lewis B. Silverman, et al.. (2015). Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition. Blood. 126(23). 3792–3792. 10 indexed citations

Ribrag, Vincent, Jean‐Charles Soria, Jean‐Marie Michot, et al.. (2015). Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients. Blood. 126(23). 473–473. 33 indexed citations

Rioux, Nathalie, Heike Keilhack, Blythe Thomson, et al.. (2015). Abstract A135: Physiologically-based pharmacokinetic modeling to support clinical investigation of the EZH2 inhibitor, tazemetostat (EPZ-6438) in INI1-deficient pediatric tumors. Molecular Cancer Therapeutics. 14(12_Supplement_2). A135–A135. 2 indexed citations

Cooper, Todd M., Richard Sposto, Elena Eckroth, et al.. (2012). A Phase I Study of AC220 in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Blood. 120(21). 3605–3605. 6 indexed citations

Hijiya, Nobuko, Blythe Thomson, Michael S. Isakoff, et al.. (2011). Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 118(23). 6043–6049. 89 indexed citations

Foster, Jennifer H., Douglas S. Hawkins, Michael R. Loken, Denise A. Wells, & Blythe Thomson. (2011). Minimal residual disease detected prior to hematopoietic cell transplantation. Pediatric Blood & Cancer. 57(1). 163–165. 12 indexed citations

Xu, Min, Laura S. Finn, Karen D. Tsuchiya, et al.. (2011). Pure Erythroid Leukemia Following Precursor B-Cell Lymphoblastic Leukemia. Pediatric and Developmental Pathology. 15(1). 76–78. 2 indexed citations

Koschmann, Carl, Blythe Thomson, & Douglas S. Hawkins. (2010). No Evidence of a Trial Effect in Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia. Archives of Pediatrics and Adolescent Medicine. 164(3). 214–214. 14 indexed citations

10.

Matloub, Yousif, Bruce Bostrom, Stephen P. Hunger, et al.. (2008). Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991. Blood. 112(11). 9–9. 10 indexed citations

11.

Cripe, Timothy P., Blythe Thomson, Thomas F. Boat, & David A. Williams. (2005). Promoting Translational Research in Academic Health Centers: Navigating the ???Roadmap???. Academic Medicine. 80(11). 1012–1018. 21 indexed citations

12.

Jameson, Sean C., Blythe Thomson, Margaret H. Collins, et al.. (2004). Anti–interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. Journal of Allergy and Clinical Immunology. 113(1). 115–119. 282 indexed citations

13.

Thomson, Blythe, Julie R. Park, Judy Felgenhauer, et al.. (2004). Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. Pediatric Blood & Cancer. 43(5). 571–579. 14 indexed citations

14.

Hawkins, Douglas S., Julie R. Park, Blythe Thomson, et al.. (2004). Asparaginase Pharmacokinetics After Intensive Polyethylene Glycol-Conjugated L-Asparaginase Therapy for Children with Relapsed Acute Lymphoblastic Leukemia. Clinical Cancer Research. 10(16). 5335–5341. 88 indexed citations

15.

Hawkins, Douglas S., Judy Felgenhauer, Julie Park, et al.. (2002). Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Cancer. 95(6). 1354–1365. 28 indexed citations

16.

Thomson, Blythe, et al.. (2001). Histology-Specific Expression of a DNA Repair Protein in Pediatric Rhabdomyosarcomas. The American journal of pediatric hematology/oncology. 23(4). 234–239. 25 indexed citations

17.

Meshinchi, Soheil, Blythe Thomson, Laura S. Finn, et al.. (2001). Comparison of Multidimensional Flow Cytometry With Standard Morphology for Evaluation of Early Marrow Response in Pediatric Acute Lymphoblastic Leukemia. The American journal of pediatric hematology/oncology. 23(9). 585–590. 2 indexed citations

18.

Smith, Franklin O. & Blythe Thomson. (2000). Umbilical Cord Blood Collection, Banking, and Transplantation: Current Status and Issues Relevant to Perinatal Caregivers. Birth. 27(2). 127–135. 28 indexed citations

19.

Smith, Franklin O. & Blythe Thomson. (1999). T‐cell recovery following marrow transplant: Experience with delayed lymphocyte infusions to accelerate immune recovery or treat infectious problems. Pediatric Transplantation. 3(s1). 59–64. 5 indexed citations

20.

Radich, Jerry & Blythe Thomson. (1997). Advances in the detection of minimal residual disease. Current Opinion in Hematology. 4(4). 242–247. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact